Accretion Pharmaceuticals IPO Subscription Status: Day 3 Subscription at 3.21 Times

Accretion Pharmaceuticals's initial public offering (IPO) has shown good progress through its three-day subscription period. The ₹29.75 crore IPO has witnessed solid demand, with subscription rates opening at 1.12 times on day one, increasing to 2.37 times on day two, and reaching 3.21 times by 10:59:59 AM on the final day, demonstrating investor enthusiasm for this pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products while also offering contract manufacturing services.

Accretion Pharmaceuticals IPO retail investors segment leads with a strong 5.41 times subscription, while non-institutional investors show interest at 1.30 times and qualified institutional buyers at 0.75 times, reflecting investor confidence in this company that has expanded its global footprint to more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.
 

Subscription Status of Accretion Pharmaceuticals IPO:

Here are the subscription details for Accretion Pharmaceuticals IPO as of Day 3 (May 16, 2025, 10:59:59 AM):

Note:
 

• "Shares Offered" and "Total Amount" are calculated based on the upper price of the issue price range.
• The portions of anchor investors and market maker are not included in the total shares offered.

Key Highlights - Day 3:

• Overall subscription reaching 3.21 times, showing good investor enthusiasm
• Retail investors segment showing strong demand at 5.41 times, up from day two's 4.01 times
• NII segment showing increased interest at 1.30 times, up from day two's 0.92 times
• QIB segment maintaining steady interest at 0.75 times, unchanged from day two
• Total applications reaching 5,847, indicating widespread investor participation
• Cumulative bid amount reaching an impressive ₹84.00 crores, almost three times the issue size
• Retail category showing substantial oversubscription, reflecting strong confidence in this segment

Accretion Pharmaceuticals IPO - Day 2 Subscription at 2.37 Times

Key Highlights:

• Overall subscription rising to 2.37 times, showing more than two-fold growth from day one
• Retail investors showing strong interest at 4.01 times, more than double day one's 1.86 times
• NII segment showing increased demand at 0.92 times, up from day one's 0.51 times
• QIB segment showing improved interest at 0.75 times, up from 0.00 times on day one
• Day two momentum indicating growing investor confidence across multiple categories
• Market response highlighting interest in pharmaceutical sector
• Healthcare product manufacturing expertise attracting significant investor attention
• Second day setting stage for potentially strong final day subscription levels

Accretion Pharmaceuticals IPO - Day 1 Subscription at 1.12 Times

• Overall subscription opening at 1.12 times, showing good first-day interest
• Retail investors beginning impressively at 1.86 times, indicating strong individual investor confidence
• NII segment showing initial interest at 0.51 times, reflecting early high net-worth investor participation
• QIB segment yet to show interest at 0.00 times on day one
• Opening day demonstrating strong investor engagement especially in retail category
• Initial momentum reflecting positive assessment of pharmaceutical sector opportunity
• Manufacturing expertise in healthcare products drawing significant investor interest
• First day setting a solid subscription baseline suggesting potential for good oversubscription

About Accretion Pharmaceuticals Limited

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products. The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).

Financial performance shows strong growth with revenue increasing from ₹22.58 crores in FY2022 to ₹33.94 crores in FY2024, while profit after tax rose significantly from ₹0.08 crores to ₹3.88 crores during the same period. For the nine months ended December 2024, the company reported revenue of ₹35.75 crores with PAT of ₹5.24 crores. With 83 employees as of January 2025, the company maintains strong profitability metrics with 72.47% ROE, 36.73% ROCE, and 72.47% RONW, while operating with a debt-to-equity ratio of 2.52.
 

Highlights of the Accretion Pharmaceuticals IPO:

• IPO type: Book Building IPO
• IPO size: ₹29.75 crores
• Fresh Issue: 29.46 lakh shares
• Face value: ₹10 per share
• Issue price band: ₹96 to ₹101 per share
• Lot size: 1,200 shares
• Minimum investment for retail investors: ₹1,21,200
• Minimum investment for HNI: ₹2,42,400 (2 lots)
• Market maker reservation: 1,47,600 shares
• Anchor portion: 2,11,200 shares (₹2.13 crores raised)
• Listing at: NSE SME
• IPO opens: May 14, 2025
• IPO closes: May 16, 2025
• Allotment date: May 19, 2025
• Listing date: May 21, 2025